Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Recent signings

"future license agreements may result in a different method of revenue recognition."

Bill,

Wouldn't this statement be made to cover the possibility of royalty payments for a license in the future if a company decides to pay this way other than one time lump sum as RG alluded to in his last letter to shareholders. He said something like so far all company's have chosen lump sum payments but that TPL is offering royalty payments as an option in negotiations.

All the best,

Steve

Share
New Message
Please login to post a reply